Innovative Product Launches Phillips-Medisize has demonstrated a strong commitment to innovation with the recent launch of TheraVolt Medical Connectors and the Aria Smart Autoinjector platform, indicating ongoing investment in cutting-edge drug delivery solutions that can open doors for collaborative development projects.

Strategic Industry Engagements Active participation in major conferences such as DDL 2025 and the Respiratory Drug Delivery conference highlights the company's focus on respiratory and drug delivery technologies, presenting opportunities for partners interested in advanced medical device solutions.

Recognition and Credibility Receiving the Regents Business Partnership Award underscores Phillips-Medisize’s strong industry reputation and successful collaborations with academic institutions, which can facilitate trust and partnership opportunities with future clients or suppliers.

Focus on Digital and Connectivity Their recent emphasis on digital device integration, including wearable and connected drug delivery systems like the needle-free glucose monitor, positions the company as a forward-looking partner in digital health, ideal for technologies seeking manufacturing and development expertise.

Growth and Financial Stability With an established revenue range of $250 million to $500 million and a large workforce, Phillips-Medisize offers a stable and scalable manufacturing base for partners seeking reliable contract manufacturing and development in the medtech space.